

Tim Heise

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6389287/publications.pdf>

Version: 2024-02-01

73
papers

4,576
citations

126708

33
h-index

102304

66
g-index

74
all docs

74
docs citations

74
times ranked

3388
citing authors

#	ARTICLE	IF	CITATIONS
1	New Clamp-PID Algorithm for Automated Glucose Clamps Improves Clamp Quality. Journal of Diabetes Science and Technology, 2022, 16, 408-414.	1.3	3
2	Novel Drugs for Diabetes Therapy. Handbook of Experimental Pharmacology, 2022, , 1.	0.9	0
3	What is the value of faster acting prandial insulin? Focus on ultra rapid lispro. Diabetes, Obesity and Metabolism, 2022, 24, 1689-1701.	2.2	14
4	The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the GOLD randomized trial (GOLD5). Diabetes, Obesity and Metabolism, 2021, 23, 619-630.	2.2	9
5	ADO09, a formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 961-970.	2.2	18
6	Cover Image, Volume 23, Issue 4. Diabetes, Obesity and Metabolism, 2021, 23, .	2.2	0
7	The future of insulin therapy. Diabetes Research and Clinical Practice, 2021, 175, 108820.	1.1	30
8	Basal Insulin Fc (BIF), A Novel Insulin Suited For Once Weekly Dosing For The Treatment of Patients With Diabetes Mellitus. Journal of the Endocrine Society, 2021, 5, A329-A329.	0.1	15
9	Diabetes Technology Meeting 2020. Journal of Diabetes Science and Technology, 2021, 15, 916-960.	1.3	1
10	Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity. Clinical Diabetes and Endocrinology, 2021, 7, 16.	1.3	8
11	Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus. Clinical Pharmacokinetics, 2021, , 1.	1.6	5
12	Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 803-820.	1.8	75
13	Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. Clinical Pharmacokinetics, 2020, 59, 155-172.	1.6	35
14	Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus. Diabetes, Obesity and Metabolism, 2020, 22, 521-529.	2.2	9
15	Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by . Pediatric Diabetes, 2020, 21, 1375-1393	1.2	46
16	Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study. Clinical Pharmacokinetics, 2020, 59, 1601-1610.	1.6	27
17	Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. Diabetes, Obesity and Metabolism, 2020, 22, 1789-1798.	2.2	49
18	237-OR: Insulin Icodec: An Insulin Analog Suited for Once-Weekly Dosing in Type 2 Diabetes. Diabetes, 2020, 69, .	0.3	28

#	ARTICLE	IF	CITATIONS
19	Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences. <i>Diabetes Mellitus</i> , 2020, 23, 140-160.	0.5	0
20	Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 179-188.	5.5	116
21	The Effect of Food Intake on the Pharmacokinetics of Oral Basal Insulin: A Randomised Crossover Trial in Healthy Male Subjects. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1497-1504.	1.6	23
22	Better glycaemic control with BioChaperone glargine lispro co-formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1570-1575.	2.2	5
23	Concentrated insulins in current clinical practice. <i>Diabetes Research and Clinical Practice</i> , 2019, 148, 93-101.	1.1	24
24	BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1066-1070.	2.2	31
25	Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus. <i>Clinical Pharmacokinetics</i> , 2019, 58, 639-649.	1.6	8
26	Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 601-610.	2.2	28
27	Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 569-574.	2.2	13
28	Considering Blood Dilution improves the Precision of Continuous Whole Blood Glucose Measurements. <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 751-755.	1.3	0
29	A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3). <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 274-284.	2.4	88
30	Injecting without pressing a button: An exploratory study of a shield-triggered injection mechanism. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1140-1147.	2.2	2
31	Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog. <i>Diabetes Care</i> , 2018, 41, 531-537.	4.3	86
32	Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 356-363.	1.3	34
33	Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 145-151.	1.3	42
34	Variability of insulin degludec and glargine 300 U/mL: A matter of methodology or just marketing?. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2051-2056.	2.2	5
35	MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. <i>Lancet</i> , 2018, 391, 2607-2618.	6.3	227
36	Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2627-2632.	2.2	31

#	ARTICLE	IF	CITATIONS
37	Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 379.	3.8	520
38	A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes. <i>Clinical Pharmacokinetics</i> , 2017, 56, 551-559.	1.6	150
39	A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus. <i>Drugs and Aging</i> , 2017, 34, 29-38.	1.3	30
40	Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions. <i>Clinical Drug Investigation</i> , 2017, 37, 503-509.	1.1	28
41	Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. <i>Current Medical Research and Opinion</i> , 2017, 33, 1821-1831.	0.9	31
42	Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. Srinivas. <i>Clinical Drug Investigation</i> , 2017, 37, 885-887.	1.1	0
43	Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300%U/mL in type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1032-1039.	2.2	105
44	Improved Algorithm for Automated Glucose Clamps. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 124-130.	2.4	6
45	The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus. <i>Journal of the American Society of Hypertension</i> , 2017, 11, 604-612.	2.3	69
46	Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 33-39.	2.2	22
47	Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 3-12.	2.2	84
48	A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use. <i>Clinical Pharmacokinetics</i> , 2017, 56, 339-354.	1.6	30
49	Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 208-215.	2.2	67
50	Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus. <i>Clinical Pharmacokinetics</i> , 2017, 56, 649-660.	1.6	54
51	Euglycaemic glucose clamp: what it can and cannot do, and how to do it. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 962-972.	2.2	67
52	Design and Methods of a Randomized Trial of Continuous Glucose Monitoring in Persons With Type 1 Diabetes With Impaired Glycemic Control Treated With Multiple Daily Insulin Injections (GOLD Study). <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 754-761.	1.3	18
53	Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes. <i>Clinical Therapeutics</i> , 2016, 38, 2265-2276.	1.1	71
54	Faster Onset and Greater Early Exposure and Glucose-Lowering Effect with Faster-Acting Insulin Aspart vs. Insulin Aspart: A Pooled Analysis in Subjects with Type 1 Diabetes. <i>Canadian Journal of Diabetes</i> , 2016, 40, S57.	0.4	4

#	ARTICLE	IF	CITATIONS
55	Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus. <i>Clinical Therapeutics</i> , 2016, 38, 2248-2264.e5.	1.1	43
56	Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control. <i>Diabetes Care</i> , 2016, 39, 1486-1492.	4.3	127
57	Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action. <i>Journal of Diabetes</i> , 2016, 8, 132-138.	0.8	41
58	New Insulin Glargine 300 Units/mL Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units/mL. <i>Diabetes Care</i> , 2015, 38, 637-643.	4.3	335
59	How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 792-800.	1.3	48
60	Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1193-1201.	1.5	126
61	Assessing Pharmacokinetic Interactions Between the Sodium Glucose Cotransporter 2 Inhibitor Empagliflozin and Hydrochlorothiazide or Torasemide in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Crossover Study. <i>Clinical Therapeutics</i> , 2015, 37, 793-803.	1.1	20
62	Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region. <i>Clinical Drug Investigation</i> , 2014, 34, 673-679.	1.1	28
63	A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance. <i>Clinical Pharmacokinetics</i> , 2014, 53, 787-800.	1.6	187
64	Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2014, 5, 255-265.	1.2	61
65	Insulin Stacking Versus Therapeutic Accumulation: Understanding the Differences. <i>Endocrine Practice</i> , 2014, 20, 75-83.	1.1	66
66	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2013, 4, 331-345.	1.2	102
67	Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes. <i>Diabetes Care</i> , 2012, 35, 2626-2630.	4.3	93
68	Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2012, 3, 10.	1.2	46
69	Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2010, 33, 1288-1290.	4.3	57
70	Getting closer to physiologic insulin secretion. <i>Clinical Therapeutics</i> , 2007, 29, S161-S165.	1.1	11
71	The Effect of Insulin Antibodies on the Metabolic Action of Inhaled and Subcutaneous Insulin: A prospective randomized pharmacodynamic study. <i>Diabetes Care</i> , 2005, 28, 2161-2169.	4.3	80
72	Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes. <i>Diabetes</i> , 2004, 53, 1614-1620.	0.3	570

#	ARTICLE	IF	CITATIONS
73	Rapid and Long-Acting Analogues as an Approach to Improve Insulin Therapy: An Evidence-Based Medicine Assessment. <i>Current Pharmaceutical Design</i> , 2001, 7, 1303-1325.	0.9	44